State of Licensing in the Life Science Industry
A Global View
Much has happened recently, both in the world and in life science licensing. Here's BioSci's take on key deal changes and trends.
For the second year, COVID-19 has prompted the Licensing Executive Society to take their annual meeting virtual. While there are many disadvantages of the virtual format, it does provoke advance preparation of materials, leading to earlier “pre-print” dissemination and perhaps broader participation in the virtual event.
To that end, I’ve attached my slides and Zoom presentation of a talk entitled “The State of Licensing in the Life Science Industry – A Global View” which is due to be “presented” on September 28 at the virtual LES Annual Meeting. Here’s the full LES Annual Meeting agenda.
For the first portion of the talk, I’ve utilized BiosciDB to assemble all $50M+ biopharma licenses signed over the past three years. Here’s a link. For the IPO Class portion, I’ve updated our IPO spreadsheet through 1H2021 and also included links to all US IPOs since January 2013 here. For the M&A portion of the talk, I’ve again utilized BiosciDB to assemble all biopharma acquisitions and asset purchases signed over the past three years. Here’s a link. Finally, for the Greater China licenses portion, I’ve assembled from BiosciDB all licenses granting China rights that were signed in the past three years here.
As always, subscribers to BiosciDB.com may also access the deal press release, SEC-filed quarterly or annual financial notes disclosures and/or SEC-filed contract(s) by following the “Web Links” in these several spreadsheets.